EP
JANX icon

Essential Partners’s Janux Therapeutics JANX Stock Holding History

Essential Partners’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.21K Hold
70
– – ﹤0.01% 2113
2026
Q2 		$1.07K Buy
+70
New +$1.01K ﹤0.01% 2217
2025
Q3 		– Sell
-44
Closed -$1.02K – 2733
2025
Q2 		$1.02K Buy
+44
New +$1.16K ﹤0.01% 1512

Other funds holding JANX

Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
WTG
West Tower Group Richmond, Virginia $27M AUM 33.41% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Mather Group
Mather Group Chicago, Illinois $11.8B AUM 12.84% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners's JANX Position: Q3 2026 in Review

Essential Partners held its Janux Therapeutics (JANX) position steady in Q3 2026 at 70 shares worth $1.21K. The position accounts for ﹤0.01% of the portfolio, ranked #2113.

Essential Partners first reported a position in JANX in Q2 2025 and has held it in 3 quarters since. 10 funds tracked by Wall St. Rank hold JANX as of Q3 2026.

  • Essential Partners held 70 shares of Janux Therapeutics worth $1.21K as of Q3 2026.
  • Essential Partners left its Janux Therapeutics share count unchanged in Q3 2026.
  • Janux Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2113 holding.
  • Essential Partners first reported a position in Janux Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 10 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.